Search Results - "Pallotta, Dante Pio"

Exploring Total Immunoglobulin A's Impact on Non-Biopsy Diagnosis of Celiac Disease: Implications for Diagnostic Accuracy by Raiteri, Alberto, Granito, Alessandro, Pallotta, Dante Pio, Giamperoli, Alice, Pratelli, Agnese, Monaco, Giovanni, Faggiano, Chiara, Tovoli, Francesco

“…In the current debate surrounding the biopsy-free diagnosis of CeD, it is crucial to identify factors influencing the accuracy of results. This study…”
Get full text

Autoimmune Polyendocrine Syndromes in Adult Italian Celiac Disease Patients by Pallotta, Dante Pio, Granito, Alessandro, Raiteri, Alberto, Boe, Maria, Pratelli, Agnese, Giamperoli, Alice, Monaco, Giovanni, Faggiano, Chiara, Tovoli, Francesco

“…Celiac disease (CD) is frequently associated with other autoimmune disorders. Different studies have explored the association between CD and single autoimmune…”
Get full text

Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients? by Tovoli, Francesco, Faggiano, Chiara, Raiteri, Alberto, Giamperoli, Alice, Catenaro, Teresa, Sansone, Vito, Pallotta, Dante Pio, Granito, Alessandro

“…Background: Celiac disease (CD) follow-up is a relatively underevaluated topic. However, correct adherence to follow-up procedures is central to the early…”
Get full text

Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm? by Stefanini, Bernardo, Ielasi, Luca, Pallotta, Dante Pio, Penazza, Sofia, Marseglia, Mariarosaria, Piscaglia, Fabio

“…This review explores the evolution of cancer staging, focusing on intermediate hepatocellular carcinoma (HCC), and the challenges faced by physicians. The…”
Get full text

Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments by Tovoli, Francesco, Pallotta, Dante Pio, Sansone, Vito, Iavarone, Massimo, De Giorgio, Massimo, Ielasi, Luca, Di Costanzo, Giovan Giuseppe, Giuffrida, Paolo, Sacco, Rodolfo, Pressiani, Tiziana, Di Donato, Maria Francesca, Trevisani, Franco, Fagiuoli, Stefano, Piscaglia, Fabio, Granito, Alessandro

“…Sorafenib and other tyrosine kinase inhibitors are the current standard of care for hepatocellular carcinoma (HCC) recurring after liver transplantation (LT)…”
Get full text

Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments by Tovoli, Francesco, Pallotta, Dante Pio, Sansone, Vito, Iavarone, Massimo, De Giorgio, Massimo, Ielasi, Luca, Di Costanzo, Giovan Giuseppe, Giuffrida, Paolo, Sacco, Rodolfo, Pressiani, Tiziana, Di Donato, Maria Francesca, Trevisani, Franco, Fagiuoli, Stefano, Piscaglia, Fabio, Granito, Alessandro

Get full text

Evolution of bone densitometry parameters and risk of fracture in coeliac disease: a 10-year perspective by Tovoli, Francesco, Pallotta, Dante Pio, Giamperoli, Alice, Zavatta, Guido, Skoracka, Kinga, Raiteri, Alberto, Faggiano, Chiara, Krela-Kaźmierczak, Iwona, Granito, Alessandro

“…Background Metabolic bone disease is frequently found in patients with coeliac disease (CD). Despite its high prevalence, international guidelines are…”
Get full text

Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma by Tovoli, Francesco, Pallotta, Dante Pio, Vivaldi, Caterina, Campani, Claudia, Federico, Piera, Palloni, Andrea, Dalbeni, Andrea, Soldà, Caterina, Lani, Lorenzo, Svegliati-Baroni, Gianluca, Garajova, Ingrid, Ielasi, Luca, De Lorenzo, Stefania, Granito, Alessandro, Stefanini, Bernardo, Masi, Gianluca, Marra, Fabio, Lonardi, Sara, Brandi, Giovanni, Daniele, Bruno, Auriemma, Alessandra, Schiadà, Laura, Chen, Rusi, Piscaglia, Fabio

“…Most patients receiving atezolizumab-bevacizumab (AB) for hepatocellular carcinoma will eventually experience disease progression. Randomized clinical trials…”
Get full text